The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
Cathy Burton, MB BChir, MD, MRCP, FRCPath, St James’s University Hospital, Leeds, UK, discusses how limited access to brentuximab vedotin (BV) and PD-1 inhibitors in the UK is shaping the sequencing of treatment for relapsed Hodgkin lymphoma (HL). Dr Burton highlights the efficacy of PD-1 inhibitors prior to autologous stem cell transplant, with BV-based regimens as an effective alternative, and notes that retreatment may benefit patients who relapse after a durable remission. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
